In a general population of patients with latent TB infection (including patients with and without HIV), studies have confirmed the superior safety profile of treatment with rifampicin vs isoniazid.
Whole genome sequencing of M tuberculosis isolates can identify complete drug susceptibility profiles, allowing precise treatment in early TB infection.
The Lancet Respiratory Medicine staged a debate between proponents and opponents of pan-TB regimens to tackle the current suboptimal worldwide management of TB resistance.
Study authors assessed the relationship between children living in contact with sputum smear-positive tuberculosis patients on DOTS and children getting infected with tuberculosis or tubercular infection.
The randomized, open-label, controlled trial (Study 31/A5349) had more than 2500 participants ages 12 years and older and included 214 people with HIV.
New study published in the European Respiratory Journal suggest that in most settings, the odds of drug resistance are the same for children and adults with TB, consistent with past research.
A team of investigators conducted a phase 3, double-blind trial to assess the impact of vitamin D supplementation on risk of tuberculosis infection in public schoolchildren in Mongolia.
